AstraZeneca Buys Belgian EsoBiotec for Up to $1 Billion to Boost Cell-Therapy Portfolio by Wallstreet Journal | March 31, 2025 8:17 am | US Markets The deal includes the Belgian biotech’s in-vivo cell-therapy platform, which modifies immune cells within the patient’s body, potentially increasing access to treatment and reducing costs.
